Redirecting to http://dergipark.org.tr/_fragment?_hash=pnUjutm3J9lZH0IE8chZ-X9qyR17cee0sEkLdLKOucg&_path=id%3D1615053%26_format%3Dhtml%26_locale%3Den%26_controller%3DApp%255CController%255CSite%255CArticleController%253A%253AesiArticleStats.
Review
BibTex RIS Cite

Asemetazinin ağrı tedavisindeki yeri

Year 2025, Volume: 10 Issue: 2, 34 - 37, 27.06.2025

Hüseyin Can , Mehmet Arslan , Elif Keskin Arslan

https://doi.org/10.22391/fppc.1615053

Abstract

Analjezikler, opioid dışı, opioid ve adjuvan tedavi seçenekleri olmak üzere üç ana gruba ayrılabilir. Bu derlemede, opioid dışı grupta yer alan non-steroid anti-inflamatuar ilaçlar (NSAİİ) arasında yer alan asemetasinin ağrı tedavisindeki yeri değerlendirilmiştir. Asemetasin bir ön ilaçtır ve vücutta indometazine dönüşerek etki eder. Klinik çalışmalar asemetasinin akut ve kronik ağrı için etkili ve güvenli bir tedavi seçeneği olduğunu göstermiştir. Asemetasinin başlıca gastrointestinal yan etkileri iştahsızlık ve mide bulantısı gibi şikayetlerdir ve yan etkilerin şiddeti genellikle hafif ila orta şiddettedir. Sonuç olarak asemetasin, oral yoldan etkili olan, yeterli analjezik etkiye sahip olan, düşük gastrointestinal yan etki profiline sahip olan ve ağrı tedavisinde tolerans ve bağımlılığa neden olmayan iyi bir seçenektir.

Keywords

Asemetazin Ağrı NSAID

References

  • 1. Arslan M, Albaş S, Küçükerdem HS, Pamuk G, Can H. Vizüel Analog Skala ile Kanser Hastalarında Palyatif Ağrı Tedavisinin Etkinliğinin Değerlendirilmesi. Fam Pract Palliat Care. 2016 Apr;1(1):5-8. https://doi.org/10.22391/920.182939
  • 2. Shetty A, Delanerolle G, Cavalini H, Deng C, Yang X, Boyd A, et al. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain. Sci Rep. 2024 Jan 18;14(1):1621. https://doi.org/10.1038/s41598-023-49761-3
  • 3. Rechziegler H, von Bernuth K. Die analgetische Wirkung von Acemetacin bei rheumatischen Erkrankungen. Therapiewoche. 1985;35(4):379-84.
  • 4. Guevara-López U. Acemetacina: Características farmacológicas y clínicas. Revista Mexicana de Anestesiología. 2004;27(1):33-56.
  • 5. Abate KS, Buttaro TM. Safe and effective NSAID use. Nurse Pract. 2015 Jun 11;40(6):18-22. https://doi.org/10.1097/01.NPR.0000465125.35030.3a
  • 6. Melli M. Non-Steroidal Antiinflamatuvar İlaçlar. In: Kayaalp O, editor. Kayaalp Akılcı Tedavi Yönünden Tıbbi Farmakoloji. 13th ed. Ankara: Pelikan Yayıncılık; 2012. 869-902.
  • 7. Saul PA, Korlipara K. Acemetacin and indomethacin in the treatment of rheumatoid arthritis: a double-blind comparative study in general practice. Curr Med Res Opin. 1991;12(5):332-41. https://doi.org/10.1185/03007999109112669
  • 8. Bird HA, Grant M, Hopkins R, Sedman E, Webb FWS, Wojtulewski J. Acemetacin and naproxen in the treatment of elderly patients suffering from osteoarthritis. British Journal of Clinical Research. 1992;3:77-84.
  • 9. Dejaco C, Duftner C, Schirmer M. Lack of influence of body mass index on efficacy and tolerance of acemetacin in short-term treatment of musculoskeletal diseases. Rheumatol Int. 2007 Feb;27(4):351-5. https://doi.org/10.1007/s00296-006-0206-4
  • 10. Moore RA, Derry S, McQuay HJ. Single dose oral acemetacin for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD007589. https://doi.org/10.1002/14651858.CD007589
  • 11. Ribeiro H, Rodrigues I, Napoleão L, Lira L, Marques D, Veríssimo M, et al. Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features. Biomed Pharmacother. 2022 Jun 1;150:112958. https://doi.org/10.1016/j.biopha.2022.112958
  • 12. Chávez-Piña AE, McKnight W, Dicay M, Castañeda-Hernández G, Wallace JL. Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin. Br J Pharmacol. 2007 Nov;152(6):930-8. https://doi.org/10.1038/sj.bjp.0707451
  • 13. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6):1592-601. https://doi.org/10.1002/art.27412
  • 14. Leeb BF, Bucsi L, Keszthelyi B, Böhmova J, Valesova M, Hawel R, et al. Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib. Orthopade. 2004 Sep;33(9):1032-41. https://doi.org/10.1007/s00132-004-0670-z
  • 15. Boltze KH, Brendler O, Jacobi H, Opitz W, Raddatz S, Seidel PR, et al. Chemical structure and anti-inflammatory activity in the group of substituted indole-3-acetic acids. Arzneimittelforschung. 1980;30(8A):1314-25.
  • 16. Berk B. Acemetacin in Acute and Chronic Pain Management. Journal of Drug Delivery and Therapeutics. 2023 Jun 4;13(6):18-22. https://doi.org/10.22270/jddt.v13i6.5834
  • 17. Ortiz MI, Castañeda-Hernández G, Osorio FA. Production of Lipoxins May Explain Acemetacin-Induced Gastroprotection. Proc West Pharmacol Soc. 2006;49:19-22.
  • 18. Kitamoto O, Kobayashi H, Kaji M, Kashiwagi S, Hayashida K, Shingu T, et al. A clinical study on the effect of K-708 (acemetacin) a double blind comparative study with ibuprofen in upper respiratory tract inflammation with fever. Kansenshogaku zasshi. 1981 Sep;55(9):614-29. https://doi.org/10.11150/kansenshogakuzasshi1970.55.614
  • 19. Dell HD, Beckermann B, Doersing M, Fischer W, Kamp R, Weber J, et al. Retard effect of acemetacin from a commercial preparation--kinetics in humans following single and multiple administration. Arzneimittelforschung. 1986 Apr;36(4):747-52.
  • 20. Jones RW, Collins AJ, Notarianni LJ, Sedman E. The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. Br J Clin Pharmacol. 1991 May;31(5):543-5. https://doi.org/10.1111/j.1365-2125.1991.tb05577.x
  • 21. Micromedex®. Acemetacin [Internet]. 2017 Oct [cited 2024 Dec 15]. Available from: https://www.micromedexsolutions.com/micromedex2/librarian/CS/CF336A/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/314105/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=12308-x&contentSetId=30&title=Acemetacin&servicesTitle=Acemetacin
  • 22. Chou CT, Tsai YY. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharmacol Res. 2002;22(1):1-6.
  • 23. Kikui S, Sugiyama H, Miyahara J, Ota K, Danno D, Kashiwaya Y, Takeshima T. Acemetacin, a Prodrug of Indomethacin, Is Effective for Treatment of Hemicrania Continua: A Japanese Case Report. Brain Nerve. 2022 Oct;74(10):1215-1219.
  • 24. Bemanalizadeh M, Baghaei Oskouei H, Hadizadeh A, Dakkali MS, Qahremani R, Mansouri V. Paroxysmal hemicrania in children and adolescents: A systematic review. Headache. 2022; 62(8):952-966. https://doi.org/10.1111/head.14354
  • 25. Hazleman B, Bernstein RM. Acemetacin in the long-term therapy of rheumatoid arthritis. Curr Med Res Opin. 1993;13(2):119-26. https://doi.org/10.1185/03007999309111540
  • 26. Cebeci F, Yaşar Ş, Aytekin S, Güneş P. Acemetacin-induced fixed drug eruption. Indian J Pharmacol. 2016;48(2):219-20. https://doi.org/10.4103/0253-7613.178824

The role of acemetacin in pain management

Year 2025, Volume: 10 Issue: 2, 34 - 37, 27.06.2025

Hüseyin Can , Mehmet Arslan , Elif Keskin Arslan

https://doi.org/10.22391/fppc.1615053

Abstract

Analgesics can be divided into three main groups as non-opioid, opioid, and adjuvant treatment options. In this review, the place of acemetacin, which is among the non-steroidal anti-inflammatory drugs (NSAIDs) in the non-opioid group, in pain treatment was evaluated. Acemetacin is a prodrug and acts by converting to indomethacin in the body. Clinical studies have shown that acemetacin is an effective and safe treatment option for acute and chronic pain. The main gastrointestinal side effects of acemetacin are complaints such as loss of appetite and nausea, and the severity of the side effects is usually mild to moderate. In conclusion, acemetacin is a good option that is effective orally, has a sufficient analgesic effect, has a low gastrointestinal side effect profile, and does not cause tolerance and addiction in pain treatment.

Keywords

Acemetacin Pain NSAID

References

  • 1. Arslan M, Albaş S, Küçükerdem HS, Pamuk G, Can H. Vizüel Analog Skala ile Kanser Hastalarında Palyatif Ağrı Tedavisinin Etkinliğinin Değerlendirilmesi. Fam Pract Palliat Care. 2016 Apr;1(1):5-8. https://doi.org/10.22391/920.182939
  • 2. Shetty A, Delanerolle G, Cavalini H, Deng C, Yang X, Boyd A, et al. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain. Sci Rep. 2024 Jan 18;14(1):1621. https://doi.org/10.1038/s41598-023-49761-3
  • 3. Rechziegler H, von Bernuth K. Die analgetische Wirkung von Acemetacin bei rheumatischen Erkrankungen. Therapiewoche. 1985;35(4):379-84.
  • 4. Guevara-López U. Acemetacina: Características farmacológicas y clínicas. Revista Mexicana de Anestesiología. 2004;27(1):33-56.
  • 5. Abate KS, Buttaro TM. Safe and effective NSAID use. Nurse Pract. 2015 Jun 11;40(6):18-22. https://doi.org/10.1097/01.NPR.0000465125.35030.3a
  • 6. Melli M. Non-Steroidal Antiinflamatuvar İlaçlar. In: Kayaalp O, editor. Kayaalp Akılcı Tedavi Yönünden Tıbbi Farmakoloji. 13th ed. Ankara: Pelikan Yayıncılık; 2012. 869-902.
  • 7. Saul PA, Korlipara K. Acemetacin and indomethacin in the treatment of rheumatoid arthritis: a double-blind comparative study in general practice. Curr Med Res Opin. 1991;12(5):332-41. https://doi.org/10.1185/03007999109112669
  • 8. Bird HA, Grant M, Hopkins R, Sedman E, Webb FWS, Wojtulewski J. Acemetacin and naproxen in the treatment of elderly patients suffering from osteoarthritis. British Journal of Clinical Research. 1992;3:77-84.
  • 9. Dejaco C, Duftner C, Schirmer M. Lack of influence of body mass index on efficacy and tolerance of acemetacin in short-term treatment of musculoskeletal diseases. Rheumatol Int. 2007 Feb;27(4):351-5. https://doi.org/10.1007/s00296-006-0206-4
  • 10. Moore RA, Derry S, McQuay HJ. Single dose oral acemetacin for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD007589. https://doi.org/10.1002/14651858.CD007589
  • 11. Ribeiro H, Rodrigues I, Napoleão L, Lira L, Marques D, Veríssimo M, et al. Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features. Biomed Pharmacother. 2022 Jun 1;150:112958. https://doi.org/10.1016/j.biopha.2022.112958
  • 12. Chávez-Piña AE, McKnight W, Dicay M, Castañeda-Hernández G, Wallace JL. Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin. Br J Pharmacol. 2007 Nov;152(6):930-8. https://doi.org/10.1038/sj.bjp.0707451
  • 13. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6):1592-601. https://doi.org/10.1002/art.27412
  • 14. Leeb BF, Bucsi L, Keszthelyi B, Böhmova J, Valesova M, Hawel R, et al. Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib. Orthopade. 2004 Sep;33(9):1032-41. https://doi.org/10.1007/s00132-004-0670-z
  • 15. Boltze KH, Brendler O, Jacobi H, Opitz W, Raddatz S, Seidel PR, et al. Chemical structure and anti-inflammatory activity in the group of substituted indole-3-acetic acids. Arzneimittelforschung. 1980;30(8A):1314-25.
  • 16. Berk B. Acemetacin in Acute and Chronic Pain Management. Journal of Drug Delivery and Therapeutics. 2023 Jun 4;13(6):18-22. https://doi.org/10.22270/jddt.v13i6.5834
  • 17. Ortiz MI, Castañeda-Hernández G, Osorio FA. Production of Lipoxins May Explain Acemetacin-Induced Gastroprotection. Proc West Pharmacol Soc. 2006;49:19-22.
  • 18. Kitamoto O, Kobayashi H, Kaji M, Kashiwagi S, Hayashida K, Shingu T, et al. A clinical study on the effect of K-708 (acemetacin) a double blind comparative study with ibuprofen in upper respiratory tract inflammation with fever. Kansenshogaku zasshi. 1981 Sep;55(9):614-29. https://doi.org/10.11150/kansenshogakuzasshi1970.55.614
  • 19. Dell HD, Beckermann B, Doersing M, Fischer W, Kamp R, Weber J, et al. Retard effect of acemetacin from a commercial preparation--kinetics in humans following single and multiple administration. Arzneimittelforschung. 1986 Apr;36(4):747-52.
  • 20. Jones RW, Collins AJ, Notarianni LJ, Sedman E. The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. Br J Clin Pharmacol. 1991 May;31(5):543-5. https://doi.org/10.1111/j.1365-2125.1991.tb05577.x
  • 21. Micromedex®. Acemetacin [Internet]. 2017 Oct [cited 2024 Dec 15]. Available from: https://www.micromedexsolutions.com/micromedex2/librarian/CS/CF336A/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/314105/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=12308-x&contentSetId=30&title=Acemetacin&servicesTitle=Acemetacin
  • 22. Chou CT, Tsai YY. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharmacol Res. 2002;22(1):1-6.
  • 23. Kikui S, Sugiyama H, Miyahara J, Ota K, Danno D, Kashiwaya Y, Takeshima T. Acemetacin, a Prodrug of Indomethacin, Is Effective for Treatment of Hemicrania Continua: A Japanese Case Report. Brain Nerve. 2022 Oct;74(10):1215-1219.
  • 24. Bemanalizadeh M, Baghaei Oskouei H, Hadizadeh A, Dakkali MS, Qahremani R, Mansouri V. Paroxysmal hemicrania in children and adolescents: A systematic review. Headache. 2022; 62(8):952-966. https://doi.org/10.1111/head.14354
  • 25. Hazleman B, Bernstein RM. Acemetacin in the long-term therapy of rheumatoid arthritis. Curr Med Res Opin. 1993;13(2):119-26. https://doi.org/10.1185/03007999309111540
  • 26. Cebeci F, Yaşar Ş, Aytekin S, Güneş P. Acemetacin-induced fixed drug eruption. Indian J Pharmacol. 2016;48(2):219-20. https://doi.org/10.4103/0253-7613.178824
There are 26 citations in total.

Details

Primary Language English
Subjects Clinical Sciences (Other)
Journal Section Review Article
Authors

Hüseyin Can 0000-0002-4686-7879

Mehmet Arslan 0000-0003-2791-4622

Elif Keskin Arslan 0000-0001-9538-4817

Publication Date June 27, 2025
Submission Date January 7, 2025
Acceptance Date March 4, 2025
Published in Issue Year 2025 Volume: 10 Issue: 2

Cite

APA Can, H., Arslan, M., & Keskin Arslan, E. (2025). The role of acemetacin in pain management. Family Practice and Palliative Care, 10(2), 34-37. https://doi.org/10.22391/fppc.1615053
AMA Can H, Arslan M, Keskin Arslan E. The role of acemetacin in pain management. Fam Pract Palliat Care. June 2025;10(2):34-37. doi:10.22391/fppc.1615053
Chicago Can, Hüseyin, Mehmet Arslan, and Elif Keskin Arslan. “The Role of Acemetacin in Pain Management”. Family Practice and Palliative Care 10, no. 2 (June 2025): 34-37. https://doi.org/10.22391/fppc.1615053.
EndNote Can H, Arslan M, Keskin Arslan E (June 1, 2025) The role of acemetacin in pain management. Family Practice and Palliative Care 10 2 34–37.
IEEE H. Can, M. Arslan, and E. Keskin Arslan, “The role of acemetacin in pain management”, Fam Pract Palliat Care, vol. 10, no. 2, pp. 34–37, 2025, doi: 10.22391/fppc.1615053.
ISNAD Can, Hüseyin et al. “The Role of Acemetacin in Pain Management”. Family Practice and Palliative Care 10/2 (June2025), 34-37. https://doi.org/10.22391/fppc.1615053.
JAMA Can H, Arslan M, Keskin Arslan E. The role of acemetacin in pain management. Fam Pract Palliat Care. 2025;10:34–37.
MLA Can, Hüseyin et al. “The Role of Acemetacin in Pain Management”. Family Practice and Palliative Care, vol. 10, no. 2, 2025, pp. 34-37, doi:10.22391/fppc.1615053.
Vancouver Can H, Arslan M, Keskin Arslan E. The role of acemetacin in pain management. Fam Pract Palliat Care. 2025;10(2):34-7.
 Download Cover Image

Family Practice and Palliative Care       ISSN 2458-8865       E-ISSN 2459-1505